DDInter1269 DDInter1631
Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may
Safinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
Nateglinide {u} (Compound) resembles {v} (Compound) Amphetamine
Nateglinide {u} (Compound) resembles {v} (Compound) Ramipril
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enalapril
Nateglinide {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
Nateglinide {u} (Compound) binds {v} (Gene) ABCC8
Nateglinide {u} (Compound) is included by {v} (Pharmacologic Class) Potassium Channel Antagonists
Nateglinide {u} (Compound) causes {v} (Side Effect) Dermatitis
Nateglinide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lipoic acid
Nateglinide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Methylcellulose
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Nateglinide (Compound) resembles Amphetamine (Compound)
Nateglinide (Compound) resembles Ramipril (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Enalapril
Nateglinide (Compound) treats type 2 diabetes mellitus (Disease)
Nateglinide (Compound) binds ABCC8 (Gene)
Nateglinide (Compound) is included by Potassium Channel Antagonists (Pharmacologic Class)
Nateglinide (Compound) causes Dermatitis (Side Effect)
Nateglinide may cause a minor interaction that can limit clinical effects when taken with Lipoic acid
Nateglinide may cause a minor interaction that can limit clinical effects when taken with Methylcellulose
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib